402 related articles for article (PubMed ID: 25077370)
1. COX-2, p16 and Ki67 expression in DCIS, microinvasive and early invasive breast carcinoma with extensive intraductal component.
Bartova M; Ondrias F; Muy-Kheng T; Kastner M; Singer Ch; Pohlodek K
Bratisl Lek Listy; 2014; 115(7):445-51. PubMed ID: 25077370
[TBL] [Abstract][Full Text] [Related]
2. Biomarker expression and risk of subsequent tumors after initial ductal carcinoma in situ diagnosis.
Kerlikowske K; Molinaro AM; Gauthier ML; Berman HK; Waldman F; Bennington J; Sanchez H; Jimenez C; Stewart K; Chew K; Ljung BM; Tlsty TD
J Natl Cancer Inst; 2010 May; 102(9):627-37. PubMed ID: 20427430
[TBL] [Abstract][Full Text] [Related]
3. Expression of Her2/neu, steroid receptors (ER and PR), Ki67 and p53 in invasive mammary ductal carcinoma associated with ductal carcinoma In Situ (DCIS) Versus invasive breast cancer alone.
Mylonas I; Makovitzky J; Jeschke U; Briese V; Friese K; Gerber B
Anticancer Res; 2005; 25(3A):1719-23. PubMed ID: 16033090
[TBL] [Abstract][Full Text] [Related]
4. Co-Expression of p16, Ki67 and COX-2 Is Associated with Basal Phenotype in High-Grade Ductal Carcinoma In Situ of the Breast.
Perez AA; Balabram D; Rocha RM; da Silva Souza Á; Gobbi H
J Histochem Cytochem; 2015 Jun; 63(6):408-16. PubMed ID: 25711229
[TBL] [Abstract][Full Text] [Related]
5. Clinic-Pathological Features of Breast Ductal Carcinoma
Zheng J; Zhou T; Li F; Shi J; Zhang L
Cancer Invest; 2020 Feb; 38(2):113-121. PubMed ID: 31939679
[No Abstract] [Full Text] [Related]
6. Bax protein expression in DCIS of the breast in relation to invasive ductal carcinoma and other molecular markers.
Rehman S; Crow J; Revell PA
Pathol Oncol Res; 2000; 6(4):256-63. PubMed ID: 11173657
[TBL] [Abstract][Full Text] [Related]
7. Breast density, scintimammographic (99m)Tc(V)DMSA uptake, and calcitonin gene related peptide (CGRP) expression in mixed invasive ductal associated with extensive in situ ductal carcinoma (IDC + DCIS) and pure invasive ductal carcinoma (IDC): correlation with estrogen receptor (ER) status, proliferation index Ki-67, and histological grade.
Papantoniou V; Sotiropoulou E; Valsamaki P; Tsaroucha A; Sotiropoulou M; Ptohis N; Stipsanelli A; Dimitrakakis K; Marinopoulos S; Tsiouris S; Antsaklis A
Breast Cancer; 2011 Oct; 18(4):286-91. PubMed ID: 20143189
[TBL] [Abstract][Full Text] [Related]
8. Distribution of Hsp-27 and HER-2/neu in in situ and invasive ductal breast carcinomas.
Storm FK; Gilchrist KW; Warner TF; Mahvi DM
Ann Surg Oncol; 1995 Jan; 2(1):43-8. PubMed ID: 7530588
[TBL] [Abstract][Full Text] [Related]
9. A systematic review to establish the frequency of cyclooxygenase-2 expression in normal breast epithelium, ductal carcinoma in situ, microinvasive carcinoma of the breast and invasive breast cancer.
Glover JA; Hughes CM; Cantwell MM; Murray LJ
Br J Cancer; 2011 Jun; 105(1):13-7. PubMed ID: 21654686
[TBL] [Abstract][Full Text] [Related]
10. AgNOR analysis of atypical ductal hyperplasia and intraductal carcinoma of the breast.
Guski H; Hufnagl P; Kaufmann O; Krause M; Winzer KJ
Anal Quant Cytol Histol; 2000 Jun; 22(3):206-12. PubMed ID: 10872036
[TBL] [Abstract][Full Text] [Related]
11. Correlation of cyclooxygenase-2 and aromatase immunohistochemical expression in invasive ductal carcinoma, ductal carcinoma in situ, and adjacent normal epithelium.
Oliveira VM; Piato S; Silva MA
Breast Cancer Res Treat; 2006 Feb; 95(3):235-41. PubMed ID: 16322898
[TBL] [Abstract][Full Text] [Related]
12. Hsp90 in the continuum of breast ductal carcinogenesis: Evaluation in precursors, preinvasive and ductal carcinoma lesions.
Zagouri F; Sergentanis TN; Nonni A; Papadimitriou CA; Michalopoulos NV; Domeyer P; Theodoropoulos G; Lazaris A; Patsouris E; Zogafos E; Pazaiti A; Zografos GC
BMC Cancer; 2010 Jul; 10():353. PubMed ID: 20602789
[TBL] [Abstract][Full Text] [Related]
13. Expression of COX-2, p16, and Ki67 in the range from normal breast tissue to breast cancer.
Feriancová M; Walter I; Singer CF; Gazdarica J; Pohlodek K
Neoplasma; 2021 Mar; 68(2):342-351. PubMed ID: 33147051
[TBL] [Abstract][Full Text] [Related]
14. Are the pure in situ breast ductal carcinomas and those associated with invasive carcinoma the same?
Schorr MC; Pedrini JL; Savaris RF; Zettler CG
Appl Immunohistochem Mol Morphol; 2010 Jan; 18(1):51-4. PubMed ID: 19568168
[TBL] [Abstract][Full Text] [Related]
15. Is there a low-grade precursor pathway in breast cancer?
King TA; Sakr RA; Muhsen S; Andrade VP; Giri D; Van Zee KJ; Morrow M
Ann Surg Oncol; 2012 Apr; 19(4):1115-21. PubMed ID: 21935747
[TBL] [Abstract][Full Text] [Related]
16. Identifying a highly-aggressive DCIS subgroup by studying intra-individual DCIS heterogeneity among invasive breast cancer patients.
Pape-Zambito D; Jiang Z; Wu H; Devarajan K; Slater CM; Cai KQ; Patchefsky A; Daly MB; Chen X
PLoS One; 2014; 9(6):e100488. PubMed ID: 24978026
[TBL] [Abstract][Full Text] [Related]
17. Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma.
Moriya T; Silverberg SG
Cancer; 1994 Dec; 74(11):2972-8. PubMed ID: 7954261
[TBL] [Abstract][Full Text] [Related]
18. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems.
Leong AS; Sormunen RT; Vinyuvat S; Hamdani RW; Suthipintawong C
Am J Clin Pathol; 2001 May; 115(5):709-18. PubMed ID: 11345835
[TBL] [Abstract][Full Text] [Related]
19. Aldehyde dehydrogenase 1 expression correlates with the invasion of breast cancer.
Pan H; Wu N; Huang Y; Li Q; Liu C; Liang M; Zhou W; Liu X; Wang S
Diagn Pathol; 2015 Jun; 10():66. PubMed ID: 26070788
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of HER-2/neu and its relationship with other prognostic factors change during the progression of in situ to invasive breast cancer.
Allred DC; Clark GM; Molina R; Tandon AK; Schnitt SJ; Gilchrist KW; Osborne CK; Tormey DC; McGuire WL
Hum Pathol; 1992 Sep; 23(9):974-9. PubMed ID: 1355464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
